The Bellvitge Biomedical Research Institute (IDIBELL), as a reference center in biomedical research, promotes basic and clinical studies to address people’s health problems. Our values of integrity, commitment, passion, aspiration, transparency, and trust guide our daily work and our commitment to society.
In 2022, with almost 1,500 published articles, of which almost 600 were led by IDIBELL researchers, our research maintained its high level of quality and excellence, with an average impact factor greater than nine.
Another critical aspect of our institution is the training of new talents. Last year, nearly 50 young researchers obtained their Ph. D., thus consolidating the future of biomedical research.
At this moment, we are more than 1,500 people at IDIBELL, 37% men and 63% women. Although there is still some inequality reflected in the scissors effect, in the initial positions there are most women and in power positions men, this difference is decreasing. Year after year, we are closing the scissors.
Our dedication to obtaining resources for research is evident. We obtained 140 national and 23 international competitive projects, with financing that exceeds 25 million euros. We firmly believe that we can improve people’s quality of life through research and innovation. For this reason, we have translated our knowledge into innovations that benefit society through the creation of 133 patents and 6 spin-offs.
We also consider it essential to transfer the knowledge generated to society, so in 2022, 31 press releases and 121 news on the web shared our advances with the population. In addition, through 17 public events, 14 educational activities, and 40 informative audiovisual pieces, we have promoted awareness and empowerment of the population on health issues.
To summarize, IDIBELL is an institution committed to quality, training, and innovation in health. With our dedication, we aspire to continue being a fundamental pillar in the biomedical field and contribute to the well-being of the population.
If you want more details of the challenges achieved by IDIBELL during 2022, you can consult our annual activity report.
The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center created in 2004. It is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L’Hospitalet de Llobregat.
IDIBELL is a member of the Campus of International Excellence of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the “HR Excellence in Research” program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Center of the AECC Scientific Foundation (FCAECC).